2019年苏格兰2型糖尿病缓解的流行病学:一项基于人群的横断面研究
该研究在苏格兰≥30岁且2019年12月31日存活的2型糖尿病成人中估计缓解患病率,纳入162,316人,缓解定义为2019年最后一次HbA1c前持续≥365天无降糖治疗且所有HbA1c<48 mmol/mol。共7,710人(4.8% [95%CI 4.7 to 4.9])处于缓解,缓解与年龄≥75岁、诊断时HbA1c<48 mmol/mol、无降糖治疗史、体重减轻≥15 kg及既往减重手术相关。
要点
- 162,316名2型糖尿病成人中7,710人(4.8% [95%CI 4.7 to 4.9])处于缓解。
- 无降糖治疗史者缓解OR 14.6 [95%CI 13.7 to 15.5],既往减重手术OR 11.9 [95%CI 9.41 to 15.1]。
- 体重较诊断时减轻≥15 kg者缓解OR 4.45 [95%CI 3.89 to 5.10]。
核心结论
- 在诊断后至少1次HbA1c≥48 mmol/mol(6.5%)且2019年至少记录1次HbA1c的2型糖尿病患者中,4.8%有2型糖尿病缓解证据。
- 作者认为需要针对该人群的管理和随访指南,并可能因体重减轻和糖尿病缓解是有意还是无意而有所不同。
- 作者认为本研究结果可用于评估未来举措对2型糖尿病缓解患病率的影响。
研究设计与样本
- 横断面研究,估计苏格兰所有≥30岁、诊断为2型糖尿病且2019年12月31日存活的成人中2型糖尿病缓解的患病率。
- 缓解评估时间段为2019年1月1日至2019年12月31日。
- 缓解定义为2019年最后一次HbA1c记录日期前持续≥365天无降糖治疗(GLT)且所有HbA1c值<48 mmol/mol。
- 队列共162,316人,占符合条件人群的78.5%,所有人诊断时或诊断后至少1次HbA1c≥48 mmol/mol(6.5%)且2019年至少记录1次HbA1c。
- 采用完整数据集和多重插补数据集的多变量logistic回归分析与缓解相关的特征。
主要发现
- 队列中56%在2019年年龄≥65岁,64%患2型糖尿病至少6年,74%为白人 ethnicity,19% ethnicity数据缺失,诊断时BMI中位数32.3 kg/m2。
- 共7,710人(4.8% [95%CI 4.7 to 4.9])处于2型糖尿病缓解。
- 与45至54岁组相比,≥75岁者缓解OR 1.48 [95%CI 1.34 to 1.62] P<0.001。
- 与诊断时HbA1c 48至52 mmol/mol相比,诊断时HbA1c<48 mmol/mol者缓解OR 1.31 [95%CI 1.24 to 1.39] P<0.001。
- 与0至4.9 kg体重增加相比,诊断至2019年体重减轻≥15 kg者缓解OR 4.45 [95%CI 3.89 to 5.10] P<0.001;无既往降糖治疗史OR 14.6 [95%CI 13.7 to 15.5] P<0.001;既往减重手术OR 11.9 [95%CI 9.41 to 15.1] P<0.001。
关键数值与推荐
- 缓解定义:2019年最后一次HbA1c前持续≥365天无降糖治疗且所有HbA1c<48 mmol/mol。
- 缓解患病率:4.8% [95%CI 4.7 to 4.9],对应7,710人。
- 年龄≥75岁 vs 45至54岁:OR 1.48 [95%CI 1.34 to 1.62] P<0.001。
- 诊断时HbA1c<48 mmol/mol vs 48至52 mmol/mol:OR 1.31 [95%CI 1.24 to 1.39] P<0.001。
- 无既往降糖治疗史:OR 14.6 [95%CI 13.7 to 15.5] P<0.001;体重减轻≥15 kg vs 0至4.9 kg体重增加:OR 4.45 [95%CI 3.89 to 5.10] P<0.001;既往减重手术:OR 11.9 [95%CI 9.41 to 15.1] P<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究使用了有限的2型糖尿病缓解定义子集。
- 存在数据缺失。
- 无法识别自费减重手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical pathways are changing to incorporate support and appropriate follow-up for people to achieve remission of type 2 diabetes, but there is limited understanding of the prevalence of remission in current practice or patient characteristics associated with remission. METHODS AND FINDINGS: We carried out a cross-sectional study estimating the prevalence of remission of type 2 diabetes in all adults in Scotland aged ≥30 years diagnosed with type 2 diabetes and alive on December 31, 2019. Remission of type 2 diabetes was assessed between January 1, 2019 and December 31, 2019. We defined remission as all HbA1c values <48 mmol/mol in the absence of glucose-lowering therapy (GLT) for a continuous duration of ≥365 days before the date of the last recorded HbA1c in 2019. Multivariable logistic regression in complete and multiply imputed datasets was used to examine characteristics associated with remission. Our cohort consisted of 162,316 individuals, all of whom had at least 1 HbA1c ≥48 mmol/mol (6.5%) at or after diagnosis of diabetes and at least 1 HbA1c recorded in 2019 (78.5% of the eligible population). Over half (56%) of our cohort was aged 65 years or over in 2019, and 64% had had type 2 diabetes for at least 6 years. Our cohort was predominantly of white ethnicity (74%), and ethnicity data were missing for 19% of the cohort. Median body mass index (BMI) at diagnosis was 32.3 kg/m2. A total of 7,710 people (4.8% [95% confidence interval [CI] 4.7 to 4.9]) were in remission of type 2 diabetes. Factors associated with remission were older age (odds ratio [OR] 1.48 [95% CI 1.34 to 1.62] P < 0.001) for people aged ≥75 years compared to 45 to 54 year group), HbA1c <48 mmol/mol at diagnosis (OR 1.31 [95% CI 1.24 to 1.39] P < 0.001) compared to 48 to 52 mmol/mol), no previous history of GLT (OR 14.6 [95% CI 13.7 to 15.5] P < 0.001), weight loss from diagnosis to 2019 (OR 4.45 [95% CI 3.89 to 5.10] P < 0.001) for ≥15 kg of weight loss compared to 0 to 4.9 kg weight gain), and previous bariatric surgery (OR 11.9 [95% CI 9.41 to 15.1] P < 0.001). Limitations of the study include the use of a limited subset of possible definitions of remission of type 2 diabetes, missing data, and inability to identify self-funded bariatric surgery. CONCLUSIONS: In this study, we found that 4.8% of people with type 2 diabetes who had at least 1 HbA1c ≥48 mmol/mol (6.5%) after diagnosis of diabetes and had at least 1 HbA1c recorded in 2019 had evidence of type 2 diabetes remission. Guidelines are required for management and follow-up of this group and may differ depending on whether weight loss and remission of diabetes were intentional or unintentional. Our findings can be used to evaluate the impact of future initiatives on the prevalence of type 2 diabetes remission.
引用
- Captieux M, Fleetwood K, Kennon B, et al. Epidemiology of type 2 diabetes remission in Scotland in 2019: A cross-sectional population-based study. PLoS Med. 2021. PMID: 34727107. doi:10.1371/journal.pmed.1003828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。